William Reardon - Tekla Healthcare Independent Trustee
| HQH Stock | USD 17.69 0.26 1.49% |
Executive
Mr. William S. Reardon, CPA, is an Independent Trustee of HQ Healthcare Investors. Until 2002, Mr. Reardon was a business assurance partner in PwC Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm public clients in SECregistered equity, convertible and RD limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. From 19982000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council . During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of two developmentstage public companies, Synta Pharmaceuticals and Idera Pharmaceuticals since 2010.
| Age | 74 |
| Tenure | 14 years |
| Professional Marks | CPA |
| Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hqh.html |
William Reardon Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Reardon against Tekla Healthcare stock is an integral part of due diligence when investing in Tekla Healthcare. William Reardon insider activity provides valuable insight into whether Tekla Healthcare is net buyers or sellers over its current business cycle. Note, Tekla Healthcare insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tekla Healthcare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Reardon over two months ago Acquisition by William Reardon of 646 shares of Tekla Healthcare at 15.8551 subject to Rule 16b-3 | ||
William Reardon over three months ago Insider Trading |
Tekla Healthcare Management Efficiency
As of now, Tekla Healthcare's Return On Tangible Assets are decreasing as compared to previous years. The Tekla Healthcare's current Return On Assets is estimated to increase to 0.08, while Return On Capital Employed is forecasted to increase to (0). As of now, Tekla Healthcare's Asset Turnover is decreasing as compared to previous years. Tekla Healthcare's management efficiency ratios could be used to measure how well Tekla Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| William Ogden | Allianzgi Equity Convertible | 75 | |
| Rakesh Jain | Tekla World Healthcare | 69 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| Lisa Phelan | Cohen Steers Closed | 51 | |
| Deborah DeCotis | Allianzgi Equity Convertible | 69 | |
| Richard Cochran | Allianzgi Equity Convertible | 59 | |
| Linda Puchalski | Flaherty and Crumrine | 63 | |
| Lucinda Stebbins | Tekla Healthcare Opportunities | 73 | |
| Harriett Taggart | Eaton Vance Tax | 71 | |
| Scott Whisten | Allianzgi Equity Convertible | 49 | |
| Rakesh Jain | Tekla Healthcare Opportunities | 69 | |
| Laura Woodward | Tekla Healthcare Opportunities | 51 | |
| Albert Laskaj | Cohen And Steers | 43 | |
| Helen Peters | Eaton Vance Tax | 73 | |
| Rakesh Jain | Tekla Life Sciences | 69 | |
| CFA CFA | Royce Micro Cap | N/A | |
| Lucinda Stebbins | Tekla Life Sciences | 73 | |
| Lisa Phelan | Cohen Steers Qualityome | 52 | |
| Peter Hoglund | Royce Micro Cap | 54 | |
| Orhan Dzemaili | Allianzgi Equity Convertible | 46 | |
| Bradford Gallagher | Allianzgi Equity Convertible | 75 | |
Management Performance
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 |
Tekla Healthcare Inv Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher MBA, Senior Manager | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Dr MS, Portfolio Manager | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, CEO and President Trustee, Member of Valuation Committee, CEO of Hambrecht and Quist Capital Management LLC and President - HQL and President of Hambrecht and Quist Capital Management LLC and Trustee of HQL | ||
| Rakesh Jain, Independent Trustee | ||
| MBA MD, VP Mang | ||
| Frank Gentile, Senior Manager | ||
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | 7.31 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 895.54 M | ||||
| Shares Outstanding | 50.62 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 26.32 % | ||||
| Number Of Shares Shorted | 161.04 K | ||||
| Price To Earning | 3.38 X |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.